Connect your AI

JBIO JBIO Value of common stock issued to settle convertible senior notes

Value of common stock issued to settle convertible senior notes at other companies

Ondas, Inc. ONDS

$439.58K-96.4%

TransMedics Group, Inc.TMDX

$1K—

Jade Biosciences, Inc. Common StockJBIO

$500—

Applied DigitalAPLD

$0—

Opendoor Technologies IncOPEN

$296M—

Oscar HealthOSCR

$70.83M—

Other financials

Income statement

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

Market cap$1.33B—

Enterprise value$1.28B—

Returns & leverage

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:DebtConversionConvertedInstrumentAmount1.

The official record: JBIO’s 10-K, filed March 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's value of common stock issued to settle convertible senior notes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is JBIO's value of common stock issued to settle convertible senior notes?: JBIO (JBIO) reported value of common stock issued to settle convertible senior notes of $500 in Q4 2025.
What does value of common stock issued to settle convertible senior notes mean?: Represents the face value of debt instruments that have been extinguished or converted into common equity. This metric tracks the company's efforts to clean up its capital structure by replacing debt obligations with equity ownership. Investors use this to evaluate the impact of debt-to-equity conversions on the company's overall financial health and share count.